High INPP4B expression correlates with poor clinical outcome in AML. BM trephine sections from patients with AML (n = 205) undergoing intensive induction chemotherapy. In normal BM, only rare cells expressed INPP4B, such as megakaryocytes and occasional lymphocytes. In AML, representative cases displaying (A) low INPP4B expression (<50% blast immunoreactivity) or (B) high INPP4B expression (50% to 100% blast immunoreactivity) are shown. Kaplan-Meier survival analysis of patients with AML who received chemotherapy showed that patients with high INPP4B had significantly reduced (C) LFS and (D) OS outcomes compared with patients with low INPP4B. Worse AML (E) LFS and (F) OS outcomes were also evident for patients with intermediate cytogenetic risk.